Table 1.

Therapeutic targets for cannabinoid medicines.

Disease	Therapeutic Cannabinoids	Therapeutic Targets	Ref.
PD	Δ9-THC	Tremor	Lastres-Becker et al. [81]
	CBD	Dystonia and discinesia	Lastres-Becker et al. [81]
	WIN 55,212-2 + SR141716A (RIMONABANT)	Akinesia	Maneuf et al. [80]
	Δ9-THCV	Diskinesia	Garcia et al. [84]
HD	Δ9-THC	Hyperkinesia and choreic movements	Chiarlone et al. [102]
	CBG	Hyperkinesia	Valdeolivas et al. [104]
	Δ9-THC+ CBD (SATIVEX®)	Hyperkinesia and choreic movements	Sagredo et al. [106]
	HU210 and WIN55,212-2	Hyperkinesia	Scotter et al. [108]
AD	Δ9-THC	Behavior disorders and motor impairment	Eubanks et al. [117]
	CBD	Learning behavior	Esposito et al. [119]; Martin-Moreno et al. [120]
	WIN 55,212-2	Cognitive impairment	Martin-Moreno et al [120]
	Δ9-THC + CBD	Memory and learning impairment	Aso et al. [122]
	SYNTHETIC Δ9-THC (Dronabinol)	Nocturnal motor activity, agitation and anorexia	Walther et al. [123]
MS	Δ9-THC	Spasticity	Lyman et al. [126]
	HU210 and WIN 55,212-2	Tremor and spasticity	Molina-Holgado et al. [127]; Cabral et al. [128]; Arevalo-Martin et al. [130]
	JWH-133	Tremor and spasticity	Baker et al. [134]; Buccellato et al. [135]
	CB52	Motor impairment	Ribeiro et al. [131]
	SYNTHETIC Δ9-THC (NABILONE)	Neuropathic pain	Turcotte et al. [144]
	Δ9-THC+ CBD (SATIVEX®)	Spasticity, neuropathic pain and bladder dysfunction	Vaney et al. [14]; Wilkinson et al. [15]; Freeman et al. [145]
ALS	Δ9-THC	Motor impairment and spasticity	Raman et al. [149]
	WIN 55,212-2	Tremor and motor impairment	Bilsland et al. [150]
	AM1241	Tremor and motor impairment	Kim et al. [153]
	Δ9-THC + CBD (SATIVEX®)	Motor impairment	Moreno-Martet et al. [154]
Cerebral Ischemia and Hypoxia	CBD	Reduction of brain edema, cerebral hemodynamic impairment and seizures	Alvarez et al. [162]; Pazos et al. [166,168]
Epilepsy	CBD	Convulsions	Jones et al. [172]
	CBDV	Convulsions	Scutt et al. [176]; de Petrocellis et al. [177]
	Δ9-THCV	Convulsions	Dennis et al. [180]; Ma et al. [181]